Class action lawsuit filed against Fractyl Health over alleged securities law violations
News provided byFractyl Health, Inc · 1 min read
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) and certain of its officers, alleging securities law violations. The lawsuit, which seeks to recover damages for investors who purchased or otherwise acquired Fractyl securities between January 13, 2025, and January 29, 2026, claims that the company and its officers made false and misleading statements about the company's business, operations, and prospects.
According to the complaint, the defendants failed to disclose that Revita, Fractyl's primary product, was less effective than previously claimed. Additionally, operational issues at one or more of the REMAIN-1 Midpoint Cohort's clinical sites allegedly compromised the integrity of the clinical trial results. As a result, the company's claims about the product's clinical, regulatory, and commercial prospects were overstated, the lawsuit alleges.
Peretz Bronstein, a founding partner of Bronstein, Gewirtz & Grossman, LLC, explained, "The defendants' failure to disclose critical information has misled investors, potentially causing significant harm. We are committed to holding them accountable and ensuring that all affected investors are fairly compensated."
Investors who purchased Fractyl securities within the class period are encouraged to join the lawsuit. They can do so by visiting the firm's website at [bgandg.com/cases/fractyl-health-inc-guts-class_action_lawsuit](bgandg.com/cases/fractyl-health-inc-guts-class_action_lawsuit). Investors have until October 20, 2026, to request that the court appoint them as lead plaintiff. Participation does not require investors to act as lead plaintiffs, and there are no upfront costs.
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized firm, has a history of representing investors in securities fraud cases. The firm has recovered hundreds of millions of dollars for investors nationwide. Peretz Bronstein emphasized, "We are dedicated to restoring investor capital and ensuring corporate accountability, which is crucial for maintaining the integrity of the marketplace."
No cost to investors, as the firm represents them on a contingency fee basis, meaning that it will only be reimbursed for out-of-pocket expenses and attorneys' fees if the case is successful.